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RESULTS

PATIENTS WITHOUT KNOWN CIRRHOSIS






The overall response rate = 12.3% (n=387).




BACKGROUND

208 FM, 142 IM, 34 ID, 3 Med-Peds

Respondent demographics are outlined in Table 1.

Median Age (range)



Compared to HCV monoinfected patients, coinfected patients have:

Median Years in Practice

cirrhosis1,2

Increased incidence of hepatocellular carcinoma (HCC)4



Published AASLD guidelines recommend every 6 month ultrasound (US) as the
preferred HCC screening strategy for patients with cirrhosis.5



The majority of gastroenterologists are aware of the AASLD guidelines and apply
them to clinical practice.6



Real world surveillance practices among primary providers have not been
assessed for coinfected patients in the United States.

OBJECTIVE


Presuming that a large proportion of care of HIV/HCV coinfected patients is
rendered by their primary providers, we aimed to determine their self-reported
HCC surveillance adherence practices.

METHODS



25-question survey sent via US Mail.
Study Cohort included all Primary Care and Infectious Diseases physicians in the
US-census defined Philadelphia-Camden-Wilmington Metropolitan Statistical Area
whose mailing addresses were publicly available (n=3,160).
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HIV specialists were similarly likely to non-HIV specialists to order any imaging
(76.5% vs. 68.5%, p=0.55) or yearly imaging (64.7% vs. 47.4%, p=0.07).
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81.5% of respondents (n=345) reported being somewhat or very likely to order
any liver imaging tests (US, CT, or MRI).



Only 42.3% were adherent to HCC screening guidelines using any imaging
modality (every 6 months).



No difference in adherence was observed between HIV specialists and non-HIV
specialists (41.2% vs. 42.4%, p=1.00), or with a more liberal yearly screening
strategy (79.4% vs. 65.0%, p=0.12).



No difference in adherence was observed between University and non-University
physicians (39.1% vs. 43.1%, p=0.58).



Figure 1 delineates the percentage of respondents who reported being somewhat
or very likely to order imaging by any modality, categorized by all respondents,
HIV-specialists, and non-HIV specialists. No significant difference was observed
between any of the groups.
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53 hospitals in 11 counties in four states (PA, NJ, DE, MD) had websites with a
physician locator search function and were included in the study cohort.
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Figure 2: Self-reported frequency of ordering imaging on coinfected
patients without known cirrhosis

CONCLUSIONS


Self-reported adherence with published guidelines for HCC screening is poor among
primary providers for HIV/HCV coinfected patients, including HIV specialists and
University-based providers.



Unnecessary imaging is also frequently ordered on non-cirrhotics, particularly by
University-based providers.



Improved adherence to guidelines is needed among primary providers as over 50% of
HCC’s may be missed, and many patients may not be referred for subspecialty GI or
Liver care, where screening practices may differ.
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Figure 1: Self-reported frequency of ordering imaging on coinfected cirrhotics
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Adherence was defined as reporting any imaging test (US, CT, or MRI) ordered at
6 month intervals.



51.5 ± 11.6 (30-89)

1608 Family Medicine (FM), 1384 General Internal Med (IM),
168 Infectious Diseases (ID)

The survey measured provider demographics and likelihood of ordering liver
imaging in coinfected patients, with and without known cirrhosis.

University providers were more likely to order imaging (Figure 2, OR 2.03, 95% CI
1.03 – 3.98, p=0.049), but not significantly more likely to order yearly imaging
(p=0.07).

Table 1: Respondent Demographics

Up to 40% of patients with HIV infection in US are coinfected with Hepatitis C
(HCV).1-3
Faster progression to

49.2% would likely order at least yearly imaging



34 (8.7%) self-identified as HIV specialists (28 ID, 6 IM).



–
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The responding cohort included:

–

70.4% of respondents were somewhat or very likely to order imaging

